Document is current
Any future updates will be listed below
-
Authors
,
Rascol, Olivier
Negre-Pages, Laurence
Damier, Philippe
Delval, Arnaud
Derkinderen, Pascal
Destée, Alain
Fabbri, Margherita
Meissner, Wassilios G.
Rachdi, Amine
Tison, François
Perez-Lloret, Santiago
-
Funding
Funding for this research was provided by:
Various Funders (The project was co-funded by unrestricted and unconditional grants from the Association France-Parkinson, ADREN, Boehringer Ingelheim, Eisai, Faust Pharmaceuticals, GlaxoSmithKline, Pierre Fabre Médicaments, Solvay Pharma, Wyeth Lederlé. The project was sponsored and co-financed by LN PHARMA, which participated in the design and conduct of the study; collection, management, interpretation of the data; and preparation and review of the manuscript.)
- License Information
-
More Information
Article History
First Online: 10 January 2020
Compliance with ethical standards
:
: This project was co-funded by unrestricted and unconditional grants from the Association France-Parkinson, ADREN, Boehringer Ingelheim, Eisai, Faust Pharmaceuticals, GlaxoSmithKline, Pierre Fabre Médicaments, Solvay Pharma, and Wyeth Lederlé. The project was sponsored and co-financed by LN PHARMA, which participated in the design and conduct of the study; collection, management, and interpretation of the data; and preparation and review of the manuscript.
: Olivier Rascol has acted as a scientific advisor for drug companies developing antiparkinsonian medications (Abbott, Abbvie, Acorda, Adamas, BIAL, Biogen, Boehringer-Ingelheim, Cynapsus, GSK, Impax, Merck, Osmotica, Oxford-Biomedica, Lundbeck, Novartis, Prexton, Servier, Sunovion, TEVA, UCB and Zambon) and has received unrestricted scientific grants from academic non-profit entities (Toulouse University Hospital, French Health Ministry, MJFox Foundation, France-Parkinson, European Commission). Laurence Negre-Pages reports grants from the Association France-Parkinson, ADREN, Boehringer Ingelheim, Eisai, Faust Pharmaceuticals, GlaxoSmithKline, Pierre Fabre Médicaments, Solvay Pharma and Wyeth Lederlé for funding this project. She also owns stock options from LN PHARMA, which was one of the sponsors of this study. Philippe Damier has received honoraria for conferences from Teva and Novartis. Wassilios Meissner reports receiving a grant from the Bordeaux University Hospital for this project. Outside the present work, he has received fees for editorial activities with Springer, consultancy activities from Affiris, Biohaven, Lundbeck and Sanofi, teaching honoraria from UCB, Boehringer Ingelheim and MDS, and research support from the Michael J Fox Foundation, the University Hospital Bordeaux, the French Health Ministry, the European Community, ANR, ARAMISE, PSP France, MSA Coalition, ARAMISE and LABEX Excellence Initiative. Santiago Perez-Lloret has received honoraria from Osmotica. Arnaud Delval, Pascal Derkinderen, Alain Destée, Margherita Fabbri, Amine Rachdi and Francois Tison have no conflicts of interest to declare.
